Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026

HomeCompaniesSectorsCalendarLast night
Screens
WarningsPrice and conditionThen and nowSize bandsCeased filers
Tools
Time machinePoint in timeData exportsRun logForecast logEDGAR company search
Method
MethodCoverageAbout
Ovid Therapeutics Inc.OVID · healthcare
GradeSlothDfourth fifth of 371 graded peers; percentile 70.5, sampling error 2.5 points; lower is stronger
Rank262 of 371
ProfitabilityEpercentile 94.4
SolvencyBpercentile 23.6
Growth and financingCpercentile 47.5
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $150.9M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runwaynot computable: fortress balance sheet
Inputs computable7 of 14
Graded fromfilings received through Mar 18, 2026205 days before the rescan; every figure keyed to the SEC receipt date
Last close$2.332026-10-08; market equity $455.0M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$3NovDecJanFebMarAprMayJunJulAugSepOctD$2.34
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2018nonen/aQ2
Mar 21, 2022nonen/aQ3
Mar 21, 2025nonen/aQ2
Mar 21, 2026nonen/aQ3
Aug 21, 2026D73.0Q3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 18, 2026; the document on sec.gov.

Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 85.5%[3-4]
Short runway. cash runway is 2.5 months[5]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 94.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio17.2%[1,6-8](6.6%)94.48112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 23.6
Twelve-month failure probability0.03%0.07%17.82482026-06-30
Altman Z double-prime0.80[1,9-14](0.31)33.97562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio8.97x[9-10]2.96x19.18392025-12-31
Growth and financing, sleeve percentile 47.5
Revenue growth, three-year compound69.0%[2,15-17]10.0%8.74152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(0.9%)[1,8,18-19]2.1%53.17042025-12-31
Net share issuance, one year85.5%[3-4]2.5%80.96342026-03-16

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.123; sampling error 2.5 percentile points on 371 peers.

Among 371 Peers [top]

ABCDEJNJ, Johnson & Johnson; C, percentile 44.9; market equity $618.1BJNJLLY, ELI Lilly & Co.; C, percentile 55.7; market equity $1.1TLLYABBV, AbbVie Inc.; D, percentile 63.2; market equity $481.4BABBVGILD, Gilead Sciences, Inc.; D/E, percentile 78.9; market equity $182.4BGILDMRK, Merck & Co., Inc.; D/E, percentile 80.8; market equity $351.3BMRKAMGN, Amgen Inc.; E, percentile 85.1; market equity $220.3BAMGNOVID 70.5strongerweaker

Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.

RankCompanyPercentileLetterWarnings
257Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma, Inc. (LYEL)

Dfourth fifth; percentile 69.2

Nasdaq · Pharmaceutical Preparations

market equity $215.4M; last close $8.76

Warnings: dilution, degenerate inputs; 7 of 14 inputs

69.2Ddilution, degenerate inputs
258Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics, Inc. (IOVA)

Dfourth fifth; percentile 69.5

Nasdaq · Biological Products, (No Diagnostic Substances)

market equity $6.0B; last close $13.33

Warnings: dilution, short runway; 7 of 14 inputs

69.5Ddilution, short runway
259Scienture Holdings, Inc. (SCNX)

Scienture Holdings, Inc. (SCNX)

Dfourth fifth; percentile 69.7

Nasdaq · Pharmaceutical Preparations

market equity $158.5M; last close $3.85

Warnings: fortress balance sheet; 7 of 14 inputs

69.7Dfortress balance sheet
260Rockwell Medical, Inc. (RMTI)

Rockwell Medical, Inc. (RMTI)

Dfourth fifth; percentile 70.0

Nasdaq · Pharmaceutical Preparations

market equity $32.3M; last close $8.25

No active warnings; 9 of 14 inputs

70.0D
261Bioventus Inc. (BVS)

Bioventus Inc. (BVS)

Dfourth fifth; percentile 70.3

Nasdaq · Surgical & Medical Instruments & Apparatus

last close $12.70

No active warnings; 7 of 14 inputs

70.3D
262Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. (OVID)

Dfourth fifth; percentile 70.5

Nasdaq · Pharmaceutical Preparations

market equity $457.0M; last close $2.33

Warnings: dilution, short runway; 7 of 14 inputs

70.5Ddilution, short runway
263uniQure N.V. (QURE)

uniQure N.V. (QURE)

Dfourth fifth; percentile 70.8

Nasdaq · Pharmaceutical Preparations

market equity $1.4B; last close $22.52

Warnings: fortress balance sheet; 8 of 14 inputs

70.8Dfortress balance sheet
264Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Dfourth fifth; percentile 71.1

Nasdaq · Pharmaceutical Preparations

last close $739.13

No active warnings; 7 of 14 inputs

71.1D
265AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL)

Dfourth fifth; percentile 71.4

Nasdaq · Pharmaceutical Preparations

market equity $3.7B; last close $12.02

No active warnings; 7 of 14 inputs

71.4D
266Cumberland Pharmaceuticals Inc. (CPIX)

Cumberland Pharmaceuticals Inc. (CPIX)

Dfourth fifth; percentile 71.6

Nasdaq · Pharmaceutical Preparations

market equity $104.6M; last close $7.07

No active warnings; 10 of 14 inputs

71.6D
267Bausch & Lomb Corp. (BLCO)

Bausch & Lomb Corp. (BLCO)

Dfourth fifth; percentile 71.9

NYSE · Ophthalmic Goods

market equity $6.1B; last close $17.15

No active warnings; 7 of 14 inputs

71.9D
Peer policyLetterPercentilePeers
all graded filers, equal sleevesD77.82204
sector peers, equal sleeves (the grade)D70.5371
same exchange, equal sleevesD73.01219
sector peers, equal inputsB/C39.2371

Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month105.4%8.0%89hotter than 89 of 100 peers
Distance from 52-week high(20.9%)(31.4%)64closer to its high than 64 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(8.4%)(1.0%)35pricier than 65 of 100 peers
Book value to price0.460.2868pricier than 32 of 100 peers
Sales to price0.020.317pricier than 93 of 100 peers
Composite equity issuance, five years108.9%20.3%79more equity-funded than 79 of 100 peers
Relative strength against the sector, log excess return0.51(0.14)89ahead of 89 of 100 peers

Inputs: market equity $457.0M; EBIT -$42.4M; free cash flow -$38.3M; book equity $209.9M; sales $7.3M; cash $11.3M[20].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(18.9%)✗ fail[6,8]
Operating cash flow above zero-$38.3M✗ fail[7]
Return on assets improved(0.5 pts)✗ fail[6,8,18,21]
Operating cash flow exceeds net income-$20.9M✗ fail[6-7]
Long-term leverage felln/a[1,8,18]
Current ratio improved365.6 pts✓ pass[9-10,22-23]
No new shares issued85.5%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved7.5 pts✓ pass[2,8,15,18]
Cash, filings, liquidity
Cash and equivalents$11.3M[5]
Operating cash flow, four quarters-$54.8M[5,7,24-27]
Months of runway2.5
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$3.5M
63 sessions
Days since newest grade input205

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$150.9M2025-12-312026-03-1810-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$7.3M2025-12-312026-03-1810-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding131,874,6342026-03-162026-03-1810-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding71,109,5142025-03-072025-04-3010-K/Afiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$11.3M2026-06-302026-08-1310-Qfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$17.4M2025-12-312026-03-1810-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$38.3M2025-12-312026-03-1810-Kfiling · viewer · series
8assetsus-gaap:Assets$92.2M2024-12-312026-03-1810-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$74.4M2025-12-312026-03-1810-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$8.3M2025-12-312026-03-1810-Kfiling · viewer · series
11retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$321.7M2025-12-312026-03-1810-Kfiling · viewer · series
12operating incomeus-gaap:OperatingIncomeLoss-$42.4M2025-12-312026-03-1810-Kfiling · viewer · series
13book equityus-gaap:StockholdersEquity$130.7M2025-12-312026-03-1810-Kfiling · viewer · series
14liabilitiesus-gaap:Liabilities$20.3M2025-12-312026-03-1810-Kfiling · viewer · series
15revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$566,0002024-12-312026-03-1810-Kfiling · viewer · series
16revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$392,0002023-12-312025-03-1110-Kfiling · viewer · series
17revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$1.5M2022-12-312024-03-0810-Kfiling · viewer · series
18assetsus-gaap:Assets$144.0M2023-12-312025-03-1110-Kfiling · viewer · series
19assetsus-gaap:Assets$155.3M2022-12-312024-03-0810-Kfiling · viewer · series
20shares outstandingdei:EntityCommonStockSharesOutstanding195,297,8572026-08-112026-08-1310-Qfiling · viewer · series
21net incomeus-gaap:NetIncomeLoss-$26.4M2024-12-312026-03-1810-Kfiling · viewer · series
22current assetsus-gaap:AssetsCurrent$55.9M2024-12-312026-03-1810-Kfiling · viewer · series
23current liabilitiesus-gaap:LiabilitiesCurrent$10.5M2024-12-312026-03-1810-Kfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$31.5M2026-06-302026-08-1310-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$13.9M2026-03-312026-05-1210-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$27.9M2025-09-302025-11-1210-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$15.1M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Grade boundary. Percentile 70.5 is 9.5 points from the nearest band edge; sampling error is 2.5 points.

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.

Informational and educational only. Not investment advice. SEC and market data may contain errors.

If you have any comments about this page, the methodology and every line of code that produced it are in the public repository. However, due to the limited number of personnel, we are unable to provide a direct response.

Pages
Home · Companies · Sectors · Calendar · Last night
Screens
Warnings · Price and condition · Then and now · Size bands · Ceased filers
Tools
Time machine · Point in time · Data exports · Run log · Forecast log · EDGAR company search
Method
Method · Coverage · About
Source
GitHub · ezrakruger.cc
Photographs from Wikimedia Commons

bull: Raphael Schön from Vienna, Austria, CC BY 2.0; bear: U. S. Fish and Wildlife Service - Northeast Region, Public domain; elk: Oregon Department of Fish & Wildlife, Public domain; tortoise: NPS, Public domain; sloth: Charles J. Sharp, CC BY-SA 3.0; fox: Cp9asngf, CC BY-SA 4.0; sector-business_equipment: Sangitiana Fararano, CC BY-SA 2.0; sector-healthcare: User:Squidonius, myself, and User:Beliason (assumed)., CC BY-SA 4.0; sector-manufacturing: unknown, CC BY-SA 2.0; sector-shops: Wilfredor, CC BY-SA 4.0; sector-consumer_nondurables: Nielsoncaetanosalmeron, CC BY 4.0; sector-utilities: Lijovklm, CC BY-SA 4.0; sector-consumer_durables: Stilfehler, CC BY-SA 4.0; sector-chemicals: PEO ACWA, CC BY 2.0; sector-energy: Arne Hückelheim, CC BY-SA 3.0; sector-telecom: Wikideas1, CC0; sector-other: Downtowngal, CC BY-SA 4.0.

Updated Oct 9, 2026